O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)

#748

Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.

Aim(s): Few data are yet available for neuroendocrine tumors (NET).

Materials and methods: Ninety-nine patients with NET were included in this retrospective study. Expression of MGMT protein was assessed by immunohistochemistry (IHC) and promoter gene methylation status (methylation specific polymerase chain reaction (MSP) and pyrosequencing (pyroS))

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Brakel B, Walter T, Hervieu V, Forestier J, Chayvialle J,

Keywords: MGMT,